Cutaneous Eruptions Associated With Tumour Infiltrating Lymphocyte Therapy: A Case Series
ABSTRACT Tumour‐infiltrating lymphocyte (TIL) therapy is a newly emerged effective treatment for advanced melanoma refractory to immune checkpoint inhibitors; however, its cutaneous adverse effects remain uncharacterized. We present the first case series describing dermatologic adverse effects associated with TIL therapy for malignant melanoma in five ...
Shannon C. Lyden +9 more
wiley +1 more source
Pembrolizumab‐Induced Subacute Cutaneous Lupus Erythematosus: A Case Report
ABSTRACT Subacute cutaneous lupus erythematosus (SCLE) is an increasingly recognized cutaneous immune‐related adverse event of immune checkpoint inhibitors. We report an 83‐year‐old woman who developed pruritic annular and polycyclic plaques 10 weeks after starting pembrolizumab for oropharyngeal squamous cell carcinoma.
Sebastiano Posenato +5 more
wiley +1 more source
Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. [PDF]
Fushimi C +17 more
europepmc +1 more source
ABSTRACT The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first‐line lenvatinib. PNI and GNRI were calculated based on
Cheng‐Wei Kuo +9 more
wiley +1 more source
Concurrent erythema multiforme and psoriasiform eruption during enfortumab vedotin plus pembrolizumab therapy for advanced urothelial carcinoma. [PDF]
Di Trolio R, Di Lorenzo G.
europepmc +1 more source
ABSTRACT Routine inflammatory and nutritional markers may help stratify progression risk in metastatic clear cell renal cell carcinoma during immunotherapy‐based treatment. This single‐center retrospective study included 237 patients who received first‐line toripalimab plus axitinib therapy.
Yun‐Feng Wu +4 more
wiley +1 more source
Danvatirsen plus Pembrolizumab versus Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (PEMDA-HN): A Randomized, Phase II Trial. [PDF]
Saba NF +10 more
europepmc +1 more source
Bilateral Ophthalmoplegia After Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma
The role of immune checkpoint inhibition (ICI) therapy in the treatment of head and neck squamous cell carcinoma (HNSCC) is expanding with increased utilization of neoadjuvant and adjuvant pembrolizumab in the setting of locally advanced disease. This report describes the presentation and management of the first known case of pembrolizumab‐induced ...
Leonard E. Estephan +3 more
wiley +1 more source
Residual Invasive Disease After Neoadjuvant Therapy in Triple-Negative Breast Cancer: Risk Stratification and Postoperative Radiotherapy-Pembrolizumab Integration. [PDF]
Jia X +6 more
europepmc +1 more source
Contemporary Treatment Patterns in Surgically Treated Temporal Bone Cancer
In a national cohort of 811 surgically treated temporal bone cancer patients, adjuvant radiation therapy was the most frequently utilized postoperative treatment (20.3%), while chemotherapy and immunotherapy were used far less frequently. Multimodal treatment, particularly combined parotidectomy and neck dissection, was strongly associated with higher ...
Raquel Rowell +4 more
wiley +1 more source

